• Home
  • Press
  • Contact
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to primary sidebar

TearClear logo

Preservative-free ophthalmic drug delivery

  • Home
  • Press
  • Contact

TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%

Boston, MA, Aug 24, 2021, Globe Newswire — 

TearClear, a late clinical stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution, 0.005%.

Approximately 30%-40% of patients who rely on preserved, chronic glaucoma therapies show signs of moderate to severe Ocular Surface Disease (OSD)1. Studies have suggested that removal of preservatives may be beneficial for the ocular health of such patients. To date, options for these patients have been less than adequate.

TearClear is the first and only company to develop products that keep BAK-preserved formulations safely in the bottle and deliver pristine, preservative-free drops of trusted medicines to the eye.

“We are confident that improving the health of the ocular surface matters,” Stuart Raetzman, TearClear’s CEO stated. “Responding to that unmet need has propelled us to this important milestone and it is what drives us to expand our efforts for other glaucoma therapies and to important therapies beyond glaucoma that intersect with OSD.”

About TearClear

TearClear is an ophthalmic pharmaceutical company that is transforming trusted drugs into best-in-class therapies. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development. This versatile platform enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. For more information, visit TearClear and connect with us on LinkedIn.

About Preservative Free

Preservatives, such as benzalkonium chloride (BAK), are necessary in ophthalmic solutions to maintain sterility. However, on the ocular surface, they have been reported to be associated with adverse effects like hyperemia, tear film instability and conjunctival inflammation potentially leading to meibomian gland dysfunction (MGD). By removing preservatives from the ocular surface, the potential for long term deleterious effects on the eye are reduced. TearClear offers the only means of delivering a preservative-free dose directly from preserved solutions.

TearClear Press Contact

  • Patrick Crowley
    859-462-4245
    pcrowley@strategicadvisersllc.com
FacebookTweetLinkedInEmailPrint

Copyright © 2017–2023 TearClear Corp · All Rights Reserved · Design and development by Sky Dog Technologies

Share this ArticleLike this article? Email it to a friend!

Email sent!